来源:市场资讯(来源:BBW咏竹坊)虽有临床管线进展的利好,但股价暴涨的更大推力来自该股票被快速纳入重要指数引发被动资金集中买入重点:药捷安康是一只典型的港股”小盘股”,在港股的实际流通股仅约550万股现有管线均在研发阶段,尚未实现商业化盈利,今年上半年的收入仅360万元莫莉近期,港股医药市场上一支上市不足三个月的次新股成为资本市场焦点,创新药企药捷安康(南京)科技股份有限公司(2617.HK)的...
Source Link来源:市场资讯(来源:BBW咏竹坊)虽有临床管线进展的利好,但股价暴涨的更大推力来自该股票被快速纳入重要指数引发被动资金集中买入重点:药捷安康是一只典型的港股”小盘股”,在港股的实际流通股仅约550万股现有管线均在研发阶段,尚未实现商业化盈利,今年上半年的收入仅360万元莫莉近期,港股医药市场上一支上市不足三个月的次新股成为资本市场焦点,创新药企药捷安康(南京)科技股份有限公司(2617.HK)的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.